HAYWARD - Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology, today announced CellFX nsPFA technology will be featured in multiple presentations at the upcoming Heart Rhythm Society (HRS) 2024 Annual Meeting in Boston, MA from May 16-19.
'We look forward to our proprietary CellFX nsPFA technology being highlighted in six total presentations and abstracts, and in a live case presentation at the prestigious HRS meeting,' said Darrin Uecker, Chief Technology Officer and Director of Pulse Biosciences. 'The preclinical and initial clinical outcomes from studies with our surgical clamp and catheter are encouraging and we continue to believe that CellFX nsPFA can meaningfully advance the treatment of atrial fibrillation.'
'Our innovative energy delivery platform technology allows us to uniquely meet the needs of both cardiac surgeons and EPs who together treat all types of patients with cardiac ailments,' added President and Chief Executive Officer Burke T. Barrett. 'I am looking forward to speaking with, now as part of Pulse Biosciences, the many providers in the clinical community I have met over the years.'
About Pulse Biosciences
Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The Company's proprietary CellFX nsPFA technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers.
Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the potential effectiveness and uniqueness of the Company's CellFX nsPFA technology to treat cardiac ailments, statements concerning pre-clinical or early clinical successes and whether they are predictive of the safety and efficacy of any medical device, and the Company's expectations, whether stated or implied, regarding whether the Company's CellFX nsPFA technology will become a disruptive and durable treatment option for treating any medical condition, and other future events. These statements are not historical facts but rather are based on Pulse Biosciences' current expectations, estimates, and projections regarding Pulse Biosciences' business, operations and other similar or related factors. Words such as 'may,' 'will,' 'could,' 'would,' 'should,' 'anticipate,' 'predict,' 'potential,' 'continue,' 'expects,' 'intends,' 'plans,' 'projects,' 'believes,' 'estimates,' and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Pulse Biosciences' control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Pulse Biosciences' filings with the Securities and Exchange Commission. Pulse Biosciences undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.
Contact:
Burke T. Barrett
Email: IR@pulsebiosciences.com
Philip Trip Taylor
Tel: 415.937.5406
PULSE BIOSCIENCES, INC. 
